| Name | Title | Contact Details |
|---|
AristaMD develops solutions to improve patient outcomes through efficiency in healthcare.
With more than 26 billion medical claims and 7 million more added every day, we have the industry`s strongest and fastest growing data framework. Add the simple, at-a-glance visuals, and the personalized expertise from our data scientists and you have a full spectrum of tools that help validate strategies and optimize workflows that benefit providers, payers, and patients across your entire system.
The Sequoia Project is a non-profit 501c3 chartered to advance implementation of secure, interoperable nationwide health information exchange. The Sequoia Project supports health IT interoperability initiatives, most notably: the eHealth Exchange, a rapidly growing community of exchange partners who share information under a common trust framework and a common set of rules; and Carequality, a public-private collaborative effort to build consensus among existing data sharing networks regarding technical specifications and best practices, much like the telecommunications industry did for linking cell phone networks. The Sequoia Project leads in cross-industry collaboration to develop implementation strategies that enable secure, interoperable nationwide exchange of health information.
Electrical Geodesics is a Eugene, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.